SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff is drawing attention amid renewed concerns about its heavy debt burden, high borrowing costs and HSBCs bearish assessment of its ability to fund growth. Traders are split between viewing the decline as an overdone move that could fuel a rebound and warning that financing risks could keep pressure on the AI infrastructure provider.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SLS is drawing attention as traders await the 80-event trigger for the Phase 3 REGAL trial of GPS; the last disclosed count was 78, and claims that the threshold has since been reached remain unconfirmed. Bulls interpret the extended trial as encouraging and speculate about a buyout or ASH update, while skeptics stress that the outcome is still uncertain and the timing unclear.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude swings on fears of Middle East supply disruptions, including reported attacks on shipping and energy infrastructure and heightened Iran-US tensions. Traders are divided between bulls focused on geopolitical supply risks and bears who see peace-deal headlines, disputed reports, or a normalization of flows unwinding the oil premium.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is drawing attention amid a sharp selloff in AI neocloud stocks, as investors weigh financing risks and warnings that some providers may not survive; traders are frustrated that IREN has lagged peers and debate whether the weakness is justified. Some point to the co-CEOs comments that data-center assets carry no debt and customer prepayments help fund GPU costs, while others remain concerned about sector-wide risk and continued selling.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins rebound toward the $83,000 area has fueled talk of a breakout and possible short squeeze, with bullish traders pointing to resilient buying. Others call the move a temporary bounce and stress that Bitcoin needs to hold key levels above $82,000$83,000 to sustain momentum.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows, amid concerns about Trumps standing ahead of the midterms and Truth Socials declining appeal, dominates discussion. The community is broadly bearish, citing weak business fundamentals and continued selling, while a few traders see scope for a short-term bounce.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhoods steep selloff and continued weakness dominate discussion, with traders pointing to analyst caution and a risk-off market ahead of earnings. Bears see more downside, while bulls argue the pullback is a buying opportunity and watch for support to hold.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegians reported Q3 outlook increase and reaffirmation of its 2026 outlook, alongside Carnivals strong results lifting cruise shares, are driving renewed interest. Bulls point to resilient bookings and heavy short interest as reasons for optimism, while others remain cautious about fuel costs, debt, and NCLHs lagging performance versus peers; squeeze talk is speculative.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Unconfirmed reports of a possible U.S.Iran deal are driving a sharp, volatile SPY rebound, with traders linking the reports and falling oil prices to the move. The community is split between chasing calls and viewing the rally as a fake-news pump that could fade, citing the lack of official confirmation and conflicting denials.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention for persistent share-price underperformance and widespread frustration with managements shift toward external acquisitions and pipeline investment, which critics fear could add debt and dilution. Bulls point to Orladeyos revenue and upcoming Netherton and Navenibart data, while bearish traders question whether those prospects can restore confidence.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BETA BIONICS, INC. (NASDAQ: BBNX) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by November 3, 2026

BETA BIONICS, INC. (NASDAQ: BBNX) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by November 3, 2026 BETA BIONICS, INC. (NASDAQ: BBNX) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a...

Beta Bionics, Inc. (BBNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Beta Bionics, Inc. (BBNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BBNX 2-WEEK DEADLINE ALERT: Beta Bionics Facing Securities Class Action, Investors with Losses Encouraged to Contact Hagens Berman

BBNX 2-WEEK DEADLINE ALERT: Beta Bionics Facing Securities Class Action, Investors with Losses Encouraged to Contact Hagens Berman BBNX 2-WEEK DEADLINE ALERT: Beta Bionics Facing Securities Class Action, Investors with Losses Encouraged to Contact Hagens BermanPR NewswireSAN FRANCISCO, Oct. 20...

Investor Alert: Beta Bionics (BBNX) has been Sued for Securities Fraud Over Alleged Misstatements made to Investors

Investor Alert: Beta Bionics (BBNX) has been Sued for Securities Fraud Over Alleged Misstatements made to Investors Investor Alert: Beta Bionics (BBNX) has been Sued for Securities Fraud Over Alleged Misstatements made to InvestorsPR NewswireNEW YORK, Oct. 20, 2026 A securities fraud class action...

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Beta Bionics, Inc. to Contact Law Firm

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Beta Bionics, Inc. to Contact Law Firm INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Beta Bionics, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 19, 2026 Beta Bionics, Inc. (NASDAQ: BBNX) shareholders should email...

Robbins LLP Reminds BBNX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Seeking Lead Plaintiff Status

Robbins LLP Reminds BBNX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Seeking Lead Plaintiff Status Robbins LLP Reminds BBNX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About...

Beta Bionics (BBNX) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 3, 2026 Lead Plaintiff Deadline

Beta Bionics (BBNX) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 3, 2026 Lead Plaintiff Deadline Beta Bionics (BBNX) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 3...

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNXPR NewswireNEW YORK, Oct. 15, 2026The lawsuit contends Beta...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BBNX

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BBNX INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and...

Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 3, 2026 - BBNX

Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 3, 2026 - BBNX Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 3, 2026 - BBNXPR...

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Beta Bionics Inc.

Beta Bionics Stock Gains After Mixed Analyst Coverage; Wolfe Bullish, Goldman Neutral

Equity

Bearish Sentiment

Shares of Beta Bionics rose Thursday following the initiation of coverage by two Wall Street financial firms on the diabetes-focused medical technology company.Beta Bionics shares climbed 6.4% to close at $15.36 on Thursday, with an additional 0.8% gain in after-hours trading.Goldman Sachs assigned Beta Bionics a ‘Neutral’ rating with a $16 price target, as its technology targets a specific portion of the Type 1 diabetes market.&nbsp;Still, current consensus expectations already account for most of its immediate growth possibilities.&nbsp;According to analyst David Roman, Beta Bionics' current valuation reflects two key factors: its projected growth positions it to outperform diabetes peers and SMID-cap medtech firms in the near term.At the same time, the valuation also prices in the expected need for capital raises to reach cash flow breakeven.Meanwhile, Wolfe Research signaled optimism&nbsp;by initiating coverage with an ‘Outperform’ rating and a $20 price target.Beta Bionics created the iLet Bionic Pancreas device, which automates insulin delivery for individuals with Type 1 diabetes.Recently, the medical technology firm posted strong Q1 2025 results, with net sales growth of 36% year over year, bringing total sales to $17.6 million.&nbsp;The company saw growth through a 360% increase in Pharmacy Benefit Plan (PBP) channel sales and a 291% rise in the installed user base, reaching over 19,000.&nbsp;Operating losses rose to $18.6 million, resulting in a net loss of $28.7 million.Beta Bionics projects FY25 revenues between $82 and $87 million and gross margins between 50% and 53% while expecting a rise in new patient starts through the PBP channel.On Stocktwits, retail sentiment was ‘neutral’ amid ‘low’ message volume.Beta Bionics stock has declined 35% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, logos of Beta Bionics are displayed on mobile phone screen and computer screen in Ankara, Turkiye on September 5, 2023. (Photo by Arda Kucukkaya/Anadolu Agency via Getty Images)

Wolfe Research initiated coverage with an ‘Outperform’ rating and a $20 target, while Goldman Sachs started at ‘Neutral’ with a $16 target, citing balanced growth prospects and valuation.

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$17.68
Prev Close	$16.84
Open	$17.13
Dividend Yield	0.00%
50-Day Moving Average	$18.99
Beta	1.53
Avg. Volume	1.52M
PE Ratio	-10.22

52-Week High	$32.71
52-Week Low	$8.80
Market Capitalization	$908.45M
EPS (Annual)	-$1.81
Price to Book	2.95
Revenue Per Employee	$237,000.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

BBNX Fundamentals